

BOARD OF PHARMACY

**OPEN SESSION AGENDA
ESSEX ROOM, 7th FLOOR
November 5, 2003**

I. CALL TO ORDER

II. SUNSHINE LAW ANNOUNCEMENT

III. ROLL CALL

IV. APPROVAL OF MINUTES

- (1) DRAFT OF OCTOBER 8, 2003 MINUTES
- (2) DRAFT OF SEPTEMBER 24, 2003 MINUTES
- (3) FINAL OF SEPTEMBER 10, 2003 MINUTES

V. SECRETARY'S REPORT AND RECOMMENDATION FOR REGISTRATION BY RECIPROCITY, EXAMINATION AND GRADE TRANSFER

VI. CONTINUING EDUCATION REPORT

VII. VIOLATIONS PAID FOR THE MONTH OF OCTOBER

VIII. CONFERENCES

(1) **NABP 100th Annual Meeting and Centennial Celebration Poster Session, April 24-27, 2004, Chicago, Ill**

(2) **NABP 2004 MPJE Time and Task Schedule**

Item-writing workshop, January 9-11, 2004, Rosemont, Ill

State-specific Review Meeting #1, January 23-25, 2004, Phoenix/Scottsdale, Ar

State-specific Review Meeting #2, August 13-15, 2004, Rosemont, Ill

IX. OLD BUSINESS

(1) **Consumer's Report Article**

October, 2003, Volume 68, No.10, "Drug Stores"

(2) NABP Report - Standards for Electronic Prescribing

Page 2 missing when originally distributed.

X. NEW BUSINESS

(1) NJ Association of Long Term Care Pharmacy Providers

Above group requesting the Board to address a return drug policy for Assisted Living Facilities similar to one allowed for Long Term Care Facilities.

XI. COMMITTEE REPORTS

(1) Technology Committee

(2) CQI Committee

XII. FYI

(1) DEA - "Control Substances Registration and Reregistration Application Fees"

New fees to be effective 12/1/03.

(2) NABP - Notification of DEA Rule titled - Implementation of the Methamphetamine Anti-proliferation Act; Thresholds for Retailers and for Distributors Required to Submit Reports under 21 U.S.C. 830(b)(3)"Mail Order Reports; Changes to Mail Order Reporting Requirements"

(3) ACCP News Release - Availability of "Pharmacotherapy Self-Assessment Program", Fourth Edition

(4) Statement of Janet Heinrich, Director, Health Care - Public Health Issues, "Prescription Drugs, State and Federal Oversight of Drug Compounding by Pharmacies"

(5) Statement by Steven K. Galson, MD, MPH, Acting Director Center for Drug Evaluation and Research, FDA " Before Senate Committee Hearing on - Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients"

XIII. ADJOURNMENT